Q-omics provides the consensus-scored MORN5 profile across patient tissues and cancer cell-line models. MORN5 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, MORN5 is differentially expressed in 12, with the highest sampling consensus in BLCA. Additionally, MORN5 RNA expression shows 12,699 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight KIRP, BLCA, and TGCT as cancer lineages where MORN5 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MORN5 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MORN5 survival associations across molecular data types. MORN5 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MORN5 RNA expression–survival associations across cancer types. High MORN5 expression shows unfavorable associations in LIHC and THCA, but favorable associations in KIRP, BRCA, UCEC and SARC. The KIRP Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .001). Together, the overview and detailed table identify KIRP as the clearest survival context for MORN5 RNA expression.
This table summarizes MORN5 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for MORN5. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MORN5 shows lower tumor expression in BLCA, KICH, KIRC, COAD, LUSC and UCEC. The BLCA box plot shows higher MORN5 RNA expression in normal versus tumor tissue (log2 FC = −3.790, t-test p < 0.001).
This table shows molecular features associated with MORN5 in patient tissues and cancer cell lines. In patient samples, MORN5 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, MORN5 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Myeloma, while CRISPR and shRNA rows add functional-dependency signals in SOFT_TISSUE and SKIN.
